Šimić, I., Potočnjak, I., Kraljičković, I., Stanić Benić, M., Čegec, I., Juričić Nahal, D. ... Božina, N. (2016). CYP2D6 *6/*6 genotype and drug interactions as
cause of haloperidol induced extrapyramidal
symptoms. Pharmacogenomics, 17. (13), 1385-1389. doi: 10.2217/pgs-2016-0069
Šimić, Iveta, et al. "CYP2D6 *6/*6 genotype and drug interactions as
cause of haloperidol induced extrapyramidal
symptoms." Pharmacogenomics, vol. 17, br. 13, 2016, str. 1385-1389. https://doi.org/10.2217/pgs-2016-0069
Šimić, Iveta, Ines Potočnjak, Iva Kraljičković, Mirjana Stanić Benić, Ivana Čegec, Danica Juričić Nahal, Lana Ganoci i Nada Božina. "CYP2D6 *6/*6 genotype and drug interactions as
cause of haloperidol induced extrapyramidal
symptoms." Pharmacogenomics 17, br. 13 (2016): 1385-1389. https://doi.org/10.2217/pgs-2016-0069
Šimić, I., et al. (2016) 'CYP2D6 *6/*6 genotype and drug interactions as
cause of haloperidol induced extrapyramidal
symptoms', Pharmacogenomics, 17(13), str. 1385-1389. doi: 10.2217/pgs-2016-0069
Šimić I, Potočnjak I, Kraljičković I, Stanić Benić M, Čegec I, Juričić Nahal D, i sur.. CYP2D6 *6/*6 genotype and drug interactions as
cause of haloperidol induced extrapyramidal
symptoms. Pharmacogenomics [Internet]. 2016. [pristupljeno 04.12.2024.];17(13):1385-1389. doi: 10.2217/pgs-2016-0069
I. Šimić, et al., "CYP2D6 *6/*6 genotype and drug interactions as
cause of haloperidol induced extrapyramidal
symptoms", Pharmacogenomics, vol. 17, br. 13, str. 1385-1389, 2016. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:199971. [Citirano: 04.12.2024.]